RxDoctor Payments Data

Sarah Valerio

Family · Greer, SCNPI 1831561919

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $69,698 of the $75,880 with a category attached, or 91.9%. AbbVie accounts for 90.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $34,918 and has fallen 77.3% since, to $7,917 in 2024. Among family clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$75,880in general payments, 2019–2025

Across 390 payments — averaging $194.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$69K
  • Biohaven Pharmaceutical Holding Company Ltd.$4K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Biogen$150
  • Biohaven Pharmaceuticals, Inc.$115
  • Argenx US, Inc.$66
  • plus $173 from 6 others

What the payments were for

  • Consulting fees$1500%
  • Speaking & faculty fees$69,69892%
  • Travel & lodging$1,0641%
  • Food & beverage$4,9627%
  • Education$70%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,880 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$31,355
Medicare patients
136
Services billed
1,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant70$96,892
QuliptaAtogepant34$55,033
Nurtec OdtRimegepant Sulfate31$37,320
Aimovig AutoinjectorErenumab-Aooe24$24,946
Emgality PenGalcanezumab-Gnlm25$16,425
Ajovy AutoinjectorFremanezumab-Vfrm19$13,189
Tegretol XrCarbamazepine11$7,478
Sumatriptan Succinate20$3,616
CarbatrolCarbamazepine12$3,580
Gabapentin125$2,806
Levetiracetam42$2,656
Memantine Hcl68$2,213
Duloxetine Hcl66$2,158
Clobazam25$2,113
Oxcarbazepine17$2,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$68,956$151,925104 claims
PfizerNurtec Odt$48$37,32031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →